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Abstract
Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated
in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-
to-severe disease. In a phase 2b dose-ranging study of baricitinib in combination with traditional disease-modifying
antirheumatic drugs (DMARDs) in RA patients, magnetic resonance imaging showed that baricitinib 2 mg or 4 mg
once daily provided dose-dependent suppression of synovitis, osteitis, erosion and cartilage loss at weeks 12 and 24
versus placebo. These findings correlated with clinical outcomes and were confirmed in three phase 3 studies (RA-
BEGIN, RA-BEAM and RA-BUILD) using X-rays to assess structural joint damage. In patients naïve to DMARDs (RA-BEGIN
study), baricitinib 4 mg once daily as monotherapy or combined with methotrexate produced smaller mean changes
in structural joint damage than methotrexate monotherapy at week 24. Differences versus methotrexate were
statistically significant for combined therapy. In patients responding inadequately to methotrexate (RA-BEAM study),
baricitinib 4 mg plus background methotrexate significantly inhibited structural joint damage at week 24 versus
placebo, and the results were comparable to those observed with adalimumab plus background methotrexate. In
patients responding inadequately to conventional synthetic DMARDs (csDMARDs; RA-BUILD study), baricitinib 4 mg
again significantly inhibited radiographic progression compared with placebo at week 24. Benefits were also observed
with baricitinib 2 mg once daily, but the effects of baricitinib 4 mg were more robust. The positive effects of baricitinib
4 mg on radiographic progression continued over 1 and 2 years in the long-term extension study RA-BEYOND, with
similar effects to adalimumab and significantly greater effects than placebo. Findings from the phase 3 studies of
patients with RA were supported by preclinical studies, which showed that baricitinib has an osteoprotective effect,
increasing mineralisation in bone-forming cells. In conclusion, baricitinib 4 mg once daily inhibits radiographic joint
damage progression in patients with moderate-to-severe RA who are naïve to DMARDs or respond inadequately to
csDMARDs, including methotrexate, and the beneficial effects are similar to those observed with adalimumab.
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Background
Rheumatoid arthritis (RA) is a chronic, inflammatory,
autoimmune disease associated with structural joint
damage leading to disability [1, 2]. Joint damage is
caused by the destruction of cartilage and bone via the
activation of chondrocytes and fibroblasts, leading to the
production of metalloproteinases and osteoclasts (bone-
resorbing cells) [2]. These events are driven by the over-
production of pro-inflammatory cytokines, such as
tumour necrosis factor-α, interleukins-6 and -17 and
macrophage colony stimulating factor, by immune cells
in the synovium [3]. The prevention of damage to cartil-
age and bone is an important goal in the treatment of
RA [4, 5], and agents that inhibit cytokine intracellular
transduction pathways have therefore been investigated
as possible treatments for the disease. One such pathway
is the Janus kinase (JAK)/signal transducers and activa-
tors of transcription (STAT) pathway [6].
Baricitinib is an orally available small molecule that re-
versibly inhibits JAK1 and JAK2, thereby blocking cyto-
kine signalling through the JAK/STAT pathway [6, 7].
The efficacy and safety of baricitinib as a treatment for
RA have been confirmed in an extensive programme of
clinical studies of patients with moderate-to-severe dis-
ease [8]. The results of these studies have shown that in
addition to reducing disease activity, baricitinib inhibits
radiographic progression of structural joint damage [9–
12], provides effective pain relief [13, 14] and improves
various patient-reported outcomes, including physical
function, fatigue, work productivity and quality of life
[13, 15–18]. Baricitinib is currently approved for the
treatment of moderate-to-severe RA in adults in more
than 70 countries worldwide, and more than 100,000 pa-
tients with RA have been treated with the drug to date
(Eli Lilly & Company, data on file).
The aim of this review is to collate and summarise all
data on the effects of baricitinib on structural joint dam-
age progression and the mechanisms underlying these
effects. Results achieved with approved doses of bariciti-
nib (2 mg or 4 mg once daily, apart from in the USA,
Canada and China, where the approved dose is 2 mg
once daily), measured through magnetic resonance im-
aging (MRI) or radiographic progression of joint erosion
and joint space narrowing, in clinical studies and post
hoc analyses of patients with RA who are naïve to
disease-modifying antirheumatic drugs (DMARDs) or
have an inadequate response to conventional synthetic
DMARDs (csDMARDs) are presented. In addition, data
from preclinical studies of baricitinib are reviewed.
MRI findings from a phase 2 study
The effects of baricitinib on joint damage progression
were investigated in a phase 2 study (NCT01185353) in
which adult patients with moderate-to-severe active RA
despite treatment with methotrexate were randomised
to placebo or once-daily baricitinib (1, 2, 4 or 8 mg) for
24 weeks [19]. Patients with radiographic evidence of
joint erosion in the hands/wrist and feet underwent MRI
of the hands/wrist at baseline and at weeks 12 and 24.
The images were scored by two expert radiologists who
were blinded to the chronologic order of the radiographs
and treatment. Images were scored for synovitis, osteitis
and bone erosion using Outcome Measures in Rheuma-
tology Clinical Trials (OMERACT) RA MRI scoring
(RAMRIS) [20] and for cartilage loss using the Cartilage
Loss Scale (CARLOS) [21]. Missing data were imputed
using last observation carried forward (LOCF) or linear
extrapolation. Results were compared between the treat-
ment groups using analysis of covariance (ANCOVA)
adjusted for baseline scores. Post hoc sensitivity analyses
were performed using alternative methods for the im-
putation of missing data. These alternative methods ex-
cluded data from patients who terminated the study
early and used baseline scores to impute post-baseline
scores based on their similarity to other randomised pa-
tients with complete data. The sensitivity analyses were
expected to have less discriminatory power than the pri-
mary analyses.
For patients who had MRI data (n = 183 for measures
of joint inflammation; n = 142 for measures of joint dam-
age), significant reductions from baseline to week 12 in
measures of joint inflammation (synovitis, osteitis and
combined inflammation scores) were observed for bari-
citinib 4 mg compared with placebo (Supplementary
Fig. 1). Some measures of joint damage at week 12 (car-
tilage loss and total joint damage) were also significantly
reduced with baricitinib 4 mg compared with placebo
(bone erosion was not significantly reduced at this time)
(Supplementary Fig. 2). Week 24 scores (n = 69)
remained stable or were further reduced for bone ero-
sion and total joint damage, but the change in cartilage
loss with baricitinib 4 mg at this time was not signifi-
cantly different versus placebo. The post hoc sensitivity
analyses confirmed the findings for bone erosion but not
for cartilage loss and total joint damage, for which no
significant effects were observed. The beneficial effects
of baricitinib 2 mg on the joints were less pronounced
than for baricitinib 4 mg, with significant change in mea-
sures of combined joint inflammation versus placebo
only at week 24, but significant improvements versus
placebo at weeks 12 and 24 in bone erosion and at week
12 in total joint damage (Supplementary Figs. 1 and 2).
Assessment of radiographic progression in phase
3 studies
Radiographic progression following treatment with bariciti-
nib has been evaluated in a number of phase 3 clinical stud-
ies, including RA-BEGIN (NCT01711359; mainly [> 91%]
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DMARD-naïve patients with early RA) [22], RA-BEAM
(NCT01710358; inadequate responders to methotrexate
with established RA) [10], RA-BUILD (NCT01721057; in-
adequate responders or those intolerant to csDMARDs
with established RA) [9] and the ongoing long-term exten-
sion study RA-BEYOND (NCT01885078) [12]. Results ob-
tained with baricitinib doses not approved by the European
Medicines Agency are excluded from this review.
In the phase 3 studies, radiographic progression was
measured using the van der Heijde modified total Sharp
score (mTSS), which includes a score for the extent of
joint erosion in 44 joints and the extent of joint space nar-
rowing in 42 joints of the hands and feet [23, 24]. The
total score ranges from 0 to 448, with higher scores indi-
cating greater joint damage. Radiographs of the hands and
feet were obtained at the screening visit (baseline) and at
the endpoint or time of rescue for patients who received
rescue treatment: baricitinib 4mg once daily from week
16 onwards (week 24 in RA-BEGIN) if tender and swollen
joint counts had improved by < 20% from baseline at
weeks 14 and 16, at the investigator’s discretion. Radio-
graphs were also obtained at the time of study discontinu-
ation if > 12 weeks had passed since the last radiograph.
All radiographs were scored centrally and independently
by two readers blinded to the chronologic order of the ra-
diographs, patient identity and treatment. The mean score
from the two readers was used unless there was disagree-
ment beyond a predefined level, in which case a third
reader adjudicated; if the adjudicator provided a score, the
two scores closest to each other were used.
Analyses were performed on the modified intent-to-
treat populations, consisting of patients with a radio-
graphic assessment at baseline and at least one assessment
during the long-term extension study. Missing data, and
data missing due to discontinuation or the initiation of
rescue therapy, were imputed using linear extrapolation,
LOCF or a mixed model for repeated measures. Radio-
graphic progression was defined as a change from baseline
to endpoint exceeding 0 or 0.5 Sharp units or the smallest
detectable change (SDC) in mTSS, which is the smallest
amount of change in score that can be assessed beyond
measurement error [25]. Least squares (LS) mean change
from baseline in mTSS, erosion score and joint space nar-
rowing score and the proportion of patients with no radio-
graphic progression were compared between treatment
groups using ANCOVA, a graphical method for multiple
testing or a logistic regression model.
Baricitinib or baricitinib plus methotrexate versus
methotrexate in DMARD-naïve patients (RA-
BEGIN)
RA-BEGIN was a phase 3, randomised, double-blind,
double-dummy, active comparator-controlled, 52-week
study in 588 patients with early RA, limited (up to three
weekly doses of methotrexate) or no prior exposure to
csDMARDs and no prior exposure to biologic DMARDs
(bDMARDs). Patients received methotrexate monotherapy
once weekly, baricitinib monotherapy 4mg once daily or
combined treatment. The study is described in detail else-
where [22]. Patient baseline characteristics are summarised
in Table 1. High-sensitivity C-reactive protein (hsCRP)
levels were around seven times the upper limit of normal
(ULN), and the majority of patients were seropositive (95–
97% rheumatoid factor [RF] positive, 89–92% anti-
citrullinated protein antibody [ACPA] positive and 87–92%
double positive across treatment groups). Baricitinib alone
or in combination with methotrexate was superior to
methotrexate monotherapy with respect to the proportion
of patients with a ≥ 20% response according to American
College of Rheumatology criteria (ACR20) at week 24,
which was 77% for baricitinib monotherapy (p ≤ 0.01 vs
methotrexate), 78% for combined therapy (p ≤ 0.001 vs
methotrexate) and 62% for methotrexate monotherapy.
At week 24, patients receiving baricitinib (as monother-
apy or combined with methotrexate) showed smaller
mean changes in mTSS, erosion score and joint space nar-
rowing than patients receiving methotrexate monother-
apy. The difference versus methotrexate was statistically
significant for mTSS and erosion score for the combin-
ation therapy group (Fig. 1a). The proportion of patients
who experienced no radiographic progression was also
greater with baricitinib than with methotrexate monother-
apy, and the difference was statistically significant for the
combination therapy group (Fig. 1b). Similar results were
observed at week 52, which marked the beginning of the
long-term extension study (Figs. 2 and 3a) [12].
A post hoc analysis of data from RA-BEGIN evaluated
the radiographic progression based on the clinical re-
sponse to treatment [11]. Patients who achieved a sus-
tained response—defined as a Disease Activity Score for
28-joint count with high-sensitivity C-reactive protein
(DAS28-hsCRP) of ≤ 3.2 (n = 212) or a Simplified Dis-
ease Activity Index (SDAI) score of ≤ 11 (n = 209) at
weeks 16, 20 and 24—were less likely to show radio-
graphic progression at week 52 than patients who did
not achieve a sustained response (n = 372) (Fig. 4). For
patients who achieved a sustained response, radiographic
progression was less likely with baricitinib 4 mg or bari-
citinib 4mg plus methotrexate than with methotrexate
monotherapy. For patients not achieving a sustained re-
sponse, radiographic progression was less likely with
combination therapy than with either monotherapy.
Baricitinib versus placebo and an active
comparator in inadequate responders to
methotrexate (RA-BEAM)
RA-BEAM was a phase 3, randomised, double-blind, pla-
cebo- and active-controlled, 52-week study in 1307
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patents with moderate-to-severe active RA and an inad-
equate response to methotrexate. The study design en-
abled the assessment of changes in structural joint
damage in addition to changes in disease activity. Pa-
tients received placebo, baricitinib 4 mg once daily or
adalimumab 40 mg subcutaneously every other week in
addition to existing background therapy. Further details
of the study are described elsewhere [10]. Patient base-
line characteristics are summarised in Table 1. As in
RA-BEGIN, the majority of patients were seropositive
(90–92% RF positive, 87–89% ACPA positive and 84–
85% double positive across treatment groups) and
hsCRP levels were around seven times the ULN. At
week 12, the ACR20 response was significantly greater
with baricitinib than with adalimumab (70% vs 61%, re-
spectively; p = 0.01). In addition, baricitinib proved su-
perior to adalimumab at week 12 with respect to
improvements in disease activity. For 1234 patients with
baseline and post-baseline radiographic data, both barici-
tinib and adalimumab significantly reduced radiographic
progression at week 24 compared with placebo, and the
level of reduction was similar for the two agents (Fig. 5).
(Note that for radiographic progression data, no statis-
tical comparison between baricitinib and adalimumab
was performed.)
At week 52, patients who initially received baricitinib
4 mg showed significantly smaller mean changes in
mTSS, erosion score and joint space narrowing than pa-
tients who initially received placebo (Fig. 2). Changes in
mTSS and erosion score were similar for baricitinib and
adalimumab, but the change in joint space narrowing was
not significantly different for adalimumab versus placebo
at year 1. The proportion of patients who experienced no
radiographic progression was also significantly greater
with baricitinib than with placebo, and the results were
similar for baricitinib and adalimumab (Fig. 3b) [12].
Baricitinib versus placebo in inadequate
responders to conventional synthetic DMARDs
(RA-BUILD)
RA-BUILD was a phase 3, randomised, double-blind,
placebo-controlled, 24-week study in 684 patients with
moderate-to-severe active RA who were naïve to
bDMARDs and had shown an inadequate response or
intolerance to ≥ 1 csDMARD. Patients received once-
daily placebo or baricitinib 2 or 4 mg added to any stable
background therapy, including methotrexate. Further
study details are presented elsewhere [9]. Patient base-
line characteristics are summarised in Table 1. A lower
proportion of patients were seropositive (75–77% RF
positive, 72–75% ACPA positive and 67–70% double
positive across treatment groups) than in RA-BEGIN
and RA-BEAM, and hsCRP levels were 5–6 times ULN.
The ACR20 response rate at week 12 was significantly
greater with baricitinib 4 mg than with placebo (62% vs
39%; p ≤ 0.001). Exploratory analyses with respect to
radiographic progression revealed a statistically signifi-
cant reduction in mTSS and joint space narrowing from
Fig. 1 Inhibition of radiographic progression at week 24 with baricitinib, methotrexate and their combination in DMARD-naïve patients with early
RA participating in RA-BEGIN [22]. a Least squares mean change from baseline in mTSS and its components, and b cumulative probability of
distribution of change from baseline in mTSS (using linear extrapolation). The table shows the proportion of patients with no radiographic
progression, measured as change in mTSS ≤ 0, ≤ 0.5 and ≤ SDC. p values for continuous and categorical data were obtained using analysis of
covariance and logistic regression, respectively. *p≤ 0.05, **p ≤ 0.01, ***p≤ 0.001 versus methotrexate. Δ, change from baseline; JSN, joint space
narrowing; LSM, least squares mean; MTX, methotrexate; SDC, smallest detectable change; mTSS, modified total Sharp score. Reproduced with
permission from Fleischmann et al. [22]
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baseline to week 24 with both baricitinib doses compared
with placebo (Fig. 6a). The reduction in joint erosion score
versus placebo was significant only for baricitinib 4mg.
The proportion of patients with no radiographic progres-
sion was also significantly greater versus placebo for pa-
tients receiving baricitinib 4mg (Fig. 6b).
Long-term data from DMARD-naïve patients and
inadequate responders to csDMARDs, including
methotrexate (RA-BEYOND)
Patients who completed baricitinib phase 2 and 3 clinical
studies were eligible to enter the ongoing long-term
extension study RA-BEYOND. At week 52, patients
from RA-BEGIN who received methotrexate or bariciti-
nib 4 mg plus methotrexate were switched to baricitinib
4 mg monotherapy. At the same timepoint, patients from
RA-BEAM who received baricitinib 4mg plus back-
ground methotrexate continued to receive the same bar-
icitinib dose plus background methotrexate, while those
who received adalimumab on background methotrexate
were switched to baricitinib 4 mg plus background
methotrexate. At week 24, patients from RA-BUILD
who received baricitinib (2 mg or 4 mg) continued to re-
ceive the same baricitinib dose, while those receiving
Fig. 2 Inhibition of radiographic progression by baricitinib at 1 and 2 years in patients originally participating in RA-BEGIN, RA-BEAM and RA-BUILD, and
then RA-BEYOND [12]. Graphs show least squares mean change from baseline (± SEM) in joint damage evaluated using a mTSS, b erosion score (ES) and c
joint space narrowing (JSN) score. The tables show the number of patients with available data at each timepoint. Missing data were imputed using linear
extrapolation. p values were obtained using a mixed model for repeated measures. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 for baricitinib 4mg versus placebo
(RA-BEAM, RA-BUILD) or methotrexate (RA-BEGIN); +p≤ 0.05, ++p≤ 0.01, +++p≤ 0.001 for adalimumab versus placebo (RA-BEAM); ‡p≤ 0.05 for baricitinib 4
mg versus baricitinib 4mg plus methotrexate (RA-BEGIN). ADA, adalimumab; Bari, baricitinib; LS, least squares; mTSS, van der Heijde modified Total Sharp
Score; PBO, placebo; SEM, standard error of the mean. Reproduced with permission from van der Heijde et al. [12]
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placebo switched to baricitinib 4 mg. Radiographic data
from patients in RA-BEYOND who participated in RA-
BEGIN [22], RA-BEAM [10] or RA-BUILD [9] were ana-
lysed at 1 and 2 years or in the event of early study ter-
mination [12]. For the RA-BEYOND analyses, baseline
was considered to be baseline of the originating study
(Supplementary Figs. 3 and 4).
For patients who originally participated in RA-BEGIN
[22], those initially receiving baricitinib 4mg plus metho-
trexate showed significantly smaller mean changes from
baseline in mTSS and erosion score than patients initially
receiving methotrexate monotherapy at 2 years (Fig. 2).
Patients initially on baricitinib 4mg monotherapy also
showed significantly fewer erosions than patients initially
taking methotrexate. The proportion of patients who
Fig. 3 Radiographic progression evaluated using cumulative percentile change in mTSS from baseline at 1 and 2 years by original randomisation
for patients participating in a RA-BEGIN, b RA-BEAM and c RA-BUILD, and then RA-BEYOND [12]. Each point represents an individual patient. The
table in each figure shows the proportion of patients with no radiographic progression (≤ SDC in mTSS). p values were obtained using a logistic
regression model with treatment included as a factor. **p≤ 0.01, ***p≤ 0.001 for baricitinib 4 mg or adalimumab versus placebo or baricitinib 4
mg plus methotrexate versus methotrexate (RA-BEGIN). Δ, change from baseline; mTSS, van der Heijde modified Total Sharp Score; n, number of
patients reaching threshold; N, number of patients with non-missing baseline and > 1 non-missing post-baseline mTSS values; N-obs, number of
patients included in analysis; SDC, smallest detectable change. Reproduced with permission from van der Heijde et al. [12]
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experienced no radiographic progression was greater with
baricitinib plus methotrexate and with baricitinib mono-
therapy than with methotrexate monotherapy, and the re-
sults were statistically significant for baricitinib plus
methotrexate versus methotrexate monotherapy (Fig. 3a).
For patients who originally participated in RA-BEAM
[10], significantly smaller mean changes in mTSS, ero-
sion score and joint space narrowing were observed at 2
years in patients who initially received baricitinib 4 mg
compared with those who initially received placebo (Fig.
2). Changes were similar for baricitinib and adalimumab.
At 2 years, the proportion of patients who experienced
no radiographic progression was also significantly greater
with baricitinib than with placebo, and results were similar
for baricitinib and adalimumab (Fig. 3b) [12].
Patients who originally participated in RA-BUILD [9]
and received baricitinib 4 mg showed significantly
smaller mean changes in mTSS and erosion score at 1
and 2 years than patients who initially received placebo
(Fig. 2). Changes with baricitinib 2 mg were smaller than
those with placebo, but the differences did not reach
statistical significance. Similarly, a greater proportion of
patients treated with baricitinib 2 mg or 4 mg experi-
enced no radiographic progression compared with pa-
tients who initially received placebo; however, the
differences were statistically significant only for the 4 mg
dose (Fig. 3c) [12].
Fig. 4 a Observed and b adjusted proportions of patients with radiographic progression (CFB in mTSS > SDC) at week 52 in patients from RA-
BEGIN with (group A) or without (group B) a sustained clinical response, defined as a DAS28-hsCRP score of ≤ 3.2 at weeks 16, 20 and 24. c
Observed and d adjusted proportions of patients with radiographic progression at week 52 in patients with (group A) or without (group B) a
sustained clinical response, defined as a SDAI score of ≤ 11 at weeks 16, 20 and 24 [11]. Adjusted proportions were estimated using a
multivariable logistic regression model. Bari, baricitinib; CFB, change from baseline; DAS28-hsCRP, Disease Activity Score for 28-joint count based
on high-sensitivity C-reactive protein; mTSS, van der Heijde-modified total Sharp score; MTX, methotrexate; SDAI, Simplified Disease Activity Index;
SDC, smallest detectable change (1.4 in the RA-BEGIN modified intent-to-treat population). Reproduced with permission from van der Heijde
et al. [11]
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For patients originating from RA-BEGIN, those ini-
tially receiving methotrexate showed a greater increase
in mTSS between years 1 and 2 (0.35 ± 0.10) than those
initially receiving baricitinib 4 mg (0.21 ± 0.10) or barici-
tinib 4 mg plus methotrexate (0.24 ± 0.09). For patients
originating from RA-BEAM and RA-BUILD, those re-
ceiving placebo showed a greater increase in mTSS be-
tween years 1 and 2 (0.56 ± 0.09 in RA-BEAM; 0.33 ±
0.09 in RA-BUILD) than patients receiving baricitinib
(0.32 ± 0.08 for baricitinib 4 mg in RA-BEAM; 0.28 ±
0.09 and 0.24 ± 0.09 for baricitinib 2 mg and 4mg, re-
spectively, in RA-BUILD) (Fig. 2) [12]. Similar results
were observed for the erosion score and joint space nar-
rowing, except that the increase in joint space narrowing
between years 1 and 2 in RA-BEGIN was similar for pa-
tients initially receiving methotrexate or monotherapy
with baricitinib 4 mg.
Radiographic progression according to baseline
characteristics
A post hoc analysis of structural damage progression
based on clinical response in RA-BEGIN suggested that,
independent of treatment (baricitinib 4 mg, methotrexate
or a combination), female sex (odds ratio [OR] 2.28, 95%
confidence interval [CI] 1.17–4.44; p = 0.015), lower
body mass index (BMI; OR 0.94, 95% CI 0.89–0.99; p =
0.025), smoking (OR 1.92, 95% CI 1.04–3.56; p = 0.037),
higher hsCRP levels (OR 1.02, 95% CI 1.01–1.03; p <
0.001) and higher Clinical Disease Activity Index
(CDAI) scores (OR 1.03, 95% CI 1.00–1.05; p = 0.038)
were significantly associated with an increased prob-
ability of such progression [11]. Thus, smokers were
at increased risk of structural damage progression
compared with non-smokers, while the odds of such
progression changed by a factor of 2.28 for being fe-
male, 0.94 for each unit increase in baseline BMI,
1.02 for each unit increase in hsCRP levels and 1.03
for each unit increase in CDAI score. The finding of
an association between lower BMI and structural
damage progression was in line with the results of
other studies suggesting that high BMI is associated
with a lower risk of such progression, possibly reflect-
ing a phenotype of less aggressive disease in patients
with higher BMI [26–29].
Similarly, a post hoc analysis from RA-BEAM showed
that lower rates of joint damage progression were ob-
served with baricitinib 4 mg compared with placebo, and
the beneficial effect of baricitinib (measured as change
in mTSS ≤ 0) was more pronounced in non-smokers
than smokers, with 83.7% (304/363) of non-smokers
showing a change in mTSS of ≤ 0 compared with 72.9%
(78/107) of smokers (interaction p value = 0.07) [30].
However, in another post hoc analysis of data from RA-
BEAM and RA-BUILD, lower rates of joint damage pro-
gression (measured by LS mean change in mTSS from
baseline to week 24 using linear extrapolation for miss-
ing data) were observed with baricitinib 4 mg compared
with placebo irrespective of smoking status (smoker/
non-smoker) and body weight (< 60, ≥ 60–< 100 and ≥
100 kg), with no statistically significant interaction be-
tween treatment and smoking status or between treat-
ment and body weight (interaction p values 0.942 and
0.566, respectively) [31].
Fig. 5 Least squares mean change in radiographic progression from baseline to week 24 in 1234 patients with moderate-to-severe active RA
participating in RA-BEAM [10]. Error bars indicate standard error. **p≤ 0.01, ***p < 0.001 for baricitinib or adalimumab versus placebo. LSM, least
squares mean; mTSS, van der Heijde modified Total Sharp Score; RA, rheumatoid arthritis. Reproduced with permission from Taylor et al. [10]
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Studies have shown that structural damage progression
in patients with RA may be inversely linked to baseline
haemoglobin (Hb) levels [32–34], which reflect
interleukin-6 and C-reactive protein levels [35, 36]; these,
in turn, correlate with structural damage progression [11,
37, 38]. This finding was supported by an analysis of data
from RA-BEGIN and RA-BEAM, which showed that
lower baseline Hb levels were associated with increased
structural damage progression at week 52 (adjusted OR
0.72, p = 0.001 in RA-BEGIN; 0.76, p < 0.001 in RA-
BEAM) [39]. Treatment with baricitinib 4mg reduced
structural damage progression at this time, independent
of baseline Hb levels (Supplementary Fig. 5).
Inhibition of bone loss
In early preclinical studies in a rat model of adjuvant-
induced arthritis, treatment with baricitinib 10mg/kg for
14 days was shown to significantly reduce joint inflamma-
tion, ankle width and bone resorption compared with
vehicle-treated animals. In addition, baricitinib prevented
Fig. 6 Results of exploratory analyses from RA-BUILD: inhibition of radiographic progression at week 24 for baricitinib versus placebo in 684
patients with moderate-to-severe active RA [9]. a Least squares mean change from baseline in mTSS and its components and b proportion of
patients with no radiographic progression. Error bars indicate standard error. *p≤ 0.05, **p ≤ 0.01 versus placebo. LS, least squares; mTSS, van der
Heijde modified Total Sharp Score; RA, rheumatoid arthritis. Figure 4a reproduced with permission from Dougados et al. [9]
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the joint destruction seen in vehicle-treated animals in the
ankles and tarsals as assessed using microcomputed tom-
ography imaging. Similar results were obtained in a mouse
model of collagen-induced arthritis [7].
A series of in vivo and in vitro analyses was conducted
in parallel with the clinical studies. The results suggested
that baricitinib also has an osteoprotective effect, increas-
ing the mineralisation capability of osteoblasts [40]. In a
murine model of serum-transfer-induced arthritis, in
which mice (n = 7–11) received baricitinib 10mg/kg or ve-
hicle twice daily by oral gavage for 14 days, mean arthritis
scores and mean ankle swelling were significantly reduced
in baricitinib-treated compared with control mice. While
arthritic control mice lost grip strength, trabecular bone
volume and thickness and cortical thickness, baricitinib-
treated mice showed a significant reduction in inflamma-
tion and arthritis-induced bone damage (Supplementary
Fig. 6). Similar results were observed with tofacitinib. In
vitro studies of murine mesenchymal stem cells that were
induced to differentiate into osteoblasts (bone-forming
cells) in the presence of baricitinib (30–300 nM) showed
that baricitinib increased mineralisation in these cells
(Supplementary Fig. 7). Similar studies in human and
murine osteoclasts (bone-resorbing cells) showed that bar-
icitinib had no direct impact on osteoclast differentiation
or their bone-resorbing capacity. Again, comparable re-
sults were observed with tofacitinib [40, 41].
Consistent with the results of preclinical studies, a
recent analysis of serum biomarkers in blood samples
from 240 patients participating in RA-BUILD showed
that treatment with baricitinib 4 mg once daily signifi-
cantly reduced serum biomarkers of joint synovial in-
flammation and tissue destruction [42]. At week 4,
serum levels of three different biomarkers of synovial
inflammation (C1M, C3M and C4M) had decreased
by 12–21%, depending on the biomarker (p < 0.01),
and these reductions were maintained at week 12 (re-
ductions of 11–27%; p < 0.001). Decreased serum
levels of a biomarker of bone resorption (CTX-I; p ≤
0.05) and a reduction in overall bone turnover of 17%
(p < 0.01) were also observed with baricitinib 4 mg at
week 12. Of note, the decrease in biomarker levels
was associated with a decrease in disease activity
composite scores, including the SDAI, CDAI, Health
Assessment Questionnaire-Disability Index (HAQ-DI)
and Disease Activity Score for 28-joint count with
erythrocyte sedimentation rate (DAS28-ESR).
Conclusions
MRI studies have shown that baricitinib 2 mg or 4
mg once daily reduces joint inflammation and dam-
age in patients with moderate-to-severe active RA,
although the difference for baricitinib 2 mg versus
placebo is not statistically significant. Phase 3 clinical
studies have confirmed these findings, showing that,
compared with placebo, baricitinib 4 mg significantly
inhibits joint inflammation and radiographic joint
damage progression in patients with an inadequate
response to csDMARDS who are biologic naïve, re-
gardless of csDMARD background medication. The
results achieved with baricitinib 4 mg are comparable
to those observed with adalimumab. Benefits are also
seen with baricitinib 2 mg once daily, but more ro-
bust benefit is observed with baricitinib 4 mg. Patient
characteristics may influence the effects of baricitinib
on radiographic progression. Preclinical studies have
shown that baricitinib has an osteoprotective effect,
increasing mineralisation in bone-forming cells, but
has no direct impact on bone-resorbing cells.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02379-6.
Additional file 1: Fig. S1. Least squares mean change from baseline to
weeks 12 (left-hand panels) and 24 (right-hand panels) in MRI measures
of inflammation: (a) synovitis, (b) osteitis and (c) combined inflammation
scores [19]. Error bars indicate standard error of the mean. p-values were
determined using analysis of covariance. Patient numbers were: placebo,
N = 48; baricitinib 1 mg, N = 27; baricitinib 2 mg, N = 29; baricitinib 4 mg,
N = 26; baricitinib 8 mg, N = 24. *p < 0.05, **p≤ 0.01, ***p≤ 0.001 versus
placebo. LSM, least squares mean; MRI, magnetic resonance imaging.
Reproduced with permission from Peterfy et al. [19]
Additional file 2: Fig. 2. Least squares mean change from baseline to
weeks 12 (left-hand panels) and 24 (right-hand panels) in MRI measures
of joint damage: (a) bone erosion, (b) cartilage loss and (c) total joint
damage [19]. Error bars indicate standard error of the mean. p-values
were determined using analysis of covariance. Patient numbers were:
placebo, N = 39; baricitinib 1 mg, N = 25; baricitinib 2 mg, N = 29;
baricitinib 4 mg, N = 25; baricitinib 8 mg, N = 24. *p < 0.05, **p < 0.01
versus placebo. LSM, least squares mean; MRI, magnetic resonance
imaging. Reproduced with permission from Peterfy et al. [19]
Additional file 3: Fig. S3. Design of the long-term extension study RA-
BEYOND. Reproduced with permission from van der Heijde et al. [12]
Additional file 4: Fig. S4. Patient disposition after 2 years of treatment
in RA-BEYOND. Reproduced with permission from van der Heijde et al.
[12]
Additional file 5: Fig. S5. Proportion of patients with RA showing
change from baseline in mTSS >SDC at week 52 according to baseline
Hb levels in (a) RA-BEGIN and (b) RA-BEAM [39]. ADA, adalimumab; Bari,
baricitinib; CFB, change from baseline; Hb, haemoglobin; IR, inadequate
response; mTSS, modified Total Sharp Score; MTX, methotrexate; PBO, pla-
cebo; SDC, smallest detectable change. Reproduced with permission from
Moeller et al. [39]
Additional file 6: Fig. S6. Arthritis and bone parameters in mice (N = 7–
11) with serum-transfer-induced arthritis treated with vehicle (controls),
baricitinib 10 mg/kg or tofacitinib 50 mg/kg twice daily for 14 days [40].
The first control group comprised mice without induced arthritis, the sec-
ond control group mice with induced arthritis. Error bars indicate stand-
ard error. p-values were determined using one-way analysis of variance
(ANOVA). *p < 0.05, **p≤ 0.01, ***p≤ 0.001 versus controls. Bari, bariciti-
nib; BV/TV, trabecular bone volume/total volume; Cort, cortical; Ct.Ar/Tt.Ar,
cortical bone area/total cross-sectional area inside the periosteal enve-
lope; Ctrl, control; STA, serum-transfer arthritis; Tofa, tofacitinib; Trab, tra-
becular. Reproduced with permission from Adam et al. [40]
Additional file 7: Fig. S7. Increase in mineralised area in murine
mesenchymal stem cell-induced osteoblasts at days 5–6 in the presence
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of baricitinib (30–300 nM) [40]. Error bars indicate standard error. p-values
were determined using repeated measures ANOVA. **p ≤ 0.01, ***p≤
0.001 versus controls. Ctrl, controls. Reproduced with permission from
Adam et al. [40]
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